GBCA Sponsors Must Conduct Human, Animal Studies To Assess Safety

US FDA is requiring additional safety measures related to GBCAs, but holds that there is no direct relationship established between gadolinium retention and kidney function.

Human kidneys

The US FDA will be requiring manufacturers of gadolinium-based contrast agents (GBCAs) to conduct human and animal studies to further assess their safety amid concerns about the retention of gadolinium in the brain and other body parts, although the agency maintains that there is no clear causal connection between remaining chemical agent and adverse event reports related to kidney function.

FDA is also adding a class warning to GBCA labels about the retention of gadolinium, the agency announced in a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Post-Marketing Regulation & Studies

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>